Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Eisai Inc., and Ipsen Pharma S.A.S.

Cancer Summaries and Commentaries™: Update from Munich: Advances in the Treatment of Gastrointestinal Cancers


Release Date: November 30, 2018
Expiration Date: November 30, 2019
Media: Internet - based

Activity Overview

This online activity updates physicians on data presented at the European Society for Medical Oncology (ESMO) meeting, held in Munich, Germany, in October 2018. PER’s Cancer Summaries and Commentaries™: Update from Munich: Advances in the Treatment of Gastrointestinal Cancers online CME activity facilitates critical assessment and, when appropriate, clinical integration of new evidence. The activity reviews 8 abstracts selected by program faculty, John Marshall, MD, and Arndt Vogel, MD, with some of the most compelling and clinically relevant GI cancer presentations from the meeting. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Benefits of Participation:
  • Learn the benefits of novel treatment strategies for patients with GI cancers
  • Hear about challenging case discussions in the treatment of patients with GI cancers
  • Understand how to apply the results of recent clinical trials to your practice
  • Learn how to manage adverse events in patients with GI cancers
  • Explore future directions for patients with GI cancers with rare genetic mutations

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Eisai Inc., and Ipsen Pharma S.A.S.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with GI cancers. Gastroenterologists, surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of GI cancers are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Detail the design, efficacy, and safety data presented on completed and ongoing clinical trials evaluating novel treatment strategies for GI cancers
  • Integrate recent trial results into evolving treatment paradigms for GI cancers
  • Identify planned/ongoing clinical trials intended to address unanswered clinical questions in the field of GI cancer, including agents that target rare gene mutations

Faculty, Staff, and Planners' Disclosures

Faculty

John Marshall, MD
Chief, Division of Hematology/Oncology
Medstar Georgetown University Hospital
Director, Ruesch Center for the Cure of GI Cancers
Washington, DC
 

Disclosures: Grant/Research Support: Roche, Amgen, Bayer, Celgene, Taiho, Merck, Indivumed, Caris. Consultant: Roche, Amgen, Bayer, Celgene, Taiho, Merck, Indivumed, Caris. Speaker’s Bureau: Roche, Amgen, Bayer, Celgene, Taiho, Merck, Indivumed, Caris.

Arndt Vogel, MD, PhD
Professor of Gastrointestinal Oncology
Hannover Medical School
Hannover, Germany
 
 

Disclosures: Grant/Research Support: Shire. Consultant: Bayer, Roche, Lilly, MSD, Novartis, Eisai, Piere Fabre. Speaker’s Bureau: Roche, MSD, Bayer, Sanofi, Novartis, Eisai, Astra, Ipsen, Servier, Piere Fabre.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By